http://rdf.ncbi.nlm.nih.gov/pubchem/patent/IE-35964-L
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2ca2e4410855da087e11bf3eea8933fa |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D501-22 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07G11-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-545 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D501-60 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D- http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D501-24 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D501-22 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D501-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D501-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D501-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D501-00 |
| filingDate | 1972-01-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 1972-07-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | IE-35964-L |
| titleOfInvention | Cephalosporin complexes |
| abstract | 1336802 Cephalosporin solvates ELI LILLY & CO 19 Jan 1972 [20 Jan 1971] 2657/72 Heading C2A Novel cephalosporin complexes of N,N- dimethylformamide (DMF) or N,N-dimethylacetamide (DMA) with a cephalosporin acid (which is defined as being any compound having the cephem ring structure with a carboxylic acid group attached in the 4-position of the dihydrothiazine ring) are prepared by: (a) mixing DMF or DMA with an ester or salt thereof of the cephalosporin acid in which the ester group is removable by treatment with a reducing agent in an acidic medium; (b) treating the mixture with a reducing agent in acidic medium to remove the ester group; and (c) adding a basic substance to raise the pH sufficiently to precipitate the desired complex. The preferred cephalosporin acids have the formula wherein R<SP>1</SP> is hydrogen or an acyl group of formula in which B is -NH 2 and W is phenyl 3- or 4- hydroxyphenyl, 4 - (α - amino - C 1 to C 3 alkyl)- phenyl, 4 - chlorophenyl, 3 - chloro- or 3,5- dichloro - 4 - hydroxyphenyl, 2- or 3 - thienyl, or sydnonyl; and A is hydrogen, -O-CO- (C 1 to C 4 alkyl), -O-CO- (C 4 to C 7 cycloalkyl), or -X-Z where X is O or S and Z is C 1 to C 4 alkyl, 1,3,4-thiadiazol-2-yl, or 1-methyl- 1H - tetrazol - 5 - yl. When the ester of the cephalosporin acid contains a free amino group, this is preferably blocked, before carrying out step (a) above, with a blocking group which is removable by acidic hydrolysis, subsequent removal of this blocking group being effected by the acidic medium used in step (b). The cephalosporin acid complex from step (c) may be purified by (d) dissolution in acidified DMF or DMA which may contain up to 40% by volume of a miscible polar liquid (e.g. water) and then (e) adding a base to reprecipitate the purified complex. The complex may be converted to the free cephalosporin acid by (f) dissolving in acidified water, heating to 40 to 70 C. and then (g) adding a base to bring the solution to the isoelectric pH of the cephalosporin, when the latter precipitates in the zwitterion form. The process (a)-(g) provides a means for obtaining pure cephalosporin acids from their impure solutions. Pharmaceutical compositions comprise an antibiotic cephalosporin, that has been prepared by the procedure (a) to (g) above, together with a suitable carrier.n[GB1336802A] |
| priorityDate | 1971-01-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 34.